Samantha D’Anna
PhD
Senior Healthcare Management Consultant
Windsor, CT, US
Samantha D’Anna is a senior healthcare management consultant with the Hartford office of Milliman. She joined the firm in 2015.
Experience
Samantha provides consulting services to insurance companies, pharmacy benefit managers, Medicare plan sponsors, government entities, and nonprofit organizations.
Her primary work includes assisting Medicare Part D plan sponsors and other groups with strategic decisions around prescription drug plan pricing within the context of the current regulatory environment.
Publications and Presentations
- Co-author, Possible outcomes of potential disclosure requirements in Medicare Part D. Milliman White Paper, March 2023.
- Co-author, Self-reported health status of Medicare Part D beneficiaries. Millman Research Paper, November 2022.
- Co-author, Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform. Milliman Briefing Note, July 2022.
- Co-author, A summary of insulin coverage in Medicare Part D. Milliman Report, June 2022.
- Co-author, Medicare Part D pharmacy price concessions at the point of sale. Milliman Report, February 2022.
- Co-author, A regulatory push to lower Part D costs at the pharmacy counter in 2023. Milliman Report, January 2022.
- Co-author, A demographic profile of Medicare Part D beneficiaries. Milliman White Paper, November 2021.
- Co-author, Reducing insulin costs for seniors: Thoughts for plan sponsors considering participation in the Medicare Part D Senior Savings Model. Milliman White Paper, March 2020.
- Co-author, A new Part D benefit design? Prescription Drug Pricing Reduction Act proposes major changes to Part D. Milliman White Paper, August 2019.
Education
- BA, Summa Cum Laude, Major: Psychology, Research Track, Minor: Neuroscience; University of Connecticut
- MA, Behavioral Neuroscience, University of Connecticut
- PhD, Behavioral Neuroscience, University of Connecticut
Publications
Read their latest work
Article
Estimated cost of potential state-level frozen formulary legislation
11 February 2025 - by Tracy Margiott, Samantha D’Anna, Sergey Rubin, Katie McBride
We estimate that proposed frozen formulary legislation could increase payer prescription drug costs by as much as $125 million in 2024 and $270 million in 2028.
Article
Pharmacy services administrative organization (PSAO) landscape
10 September 2024 - by Tory Carver, Tracy Margiott, Samantha D’Anna
We share the results of our count of pharmacy services administrative organizations for the Pharmaceutical Care Management Association.
Article
2021 Retail Pharmacy Reimbursement in Medicare Part D by Drug and Pharmacy Type
04 June 2024 - by Tory Carver, Samantha D’Anna, Tracy Margiott
We examine the 2021 retail pharmacy reimbursement in Medicare Part D by drug and pharmacy type.
Article
The shifting Medicare landscape: Results from 2024 open enrollment
02 May 2024 - by Samantha D’Anna, Tyler Engel, Katherine M. Holcomb
2024 brings significant changes to the Medicare Part D program, resulting in larger-than-average shifts in member enrollment.
Article
Possible outcomes of potential disclosure requirements in Medicare Part D
07 March 2023 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Proposed legislation would require PBMs to publish Medicare Part D rebate information, potentially altering the strategies of stakeholders.
Article
Self-reported health status of Medicare Part D beneficiaries
09 November 2022 - by Samantha D’Anna, Nolan Kurtz
We look at the metrics of Medicare beneficiaries with prescription drug coverage across ethnicity, income, and education level in the individual Part D market.
Video
Webinar: Inflation Reduction Act: What's changing in healthcare?
31 August 2022 - by Kevin Pierce, Jake K. Klaisner, Michelle (Klein) Robb, Samantha D’Anna
After more than a year of deliberation, the U.S. Senate and the U.S House of Representatives passed the Inflation Reduction Act of 2022, and it was signed into law by the President on August 16, 2022. What does this mean for healthcare?
Article
Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform
22 July 2022 - by Michelle (Klein) Robb, Kevin Pierce, Samantha D’Anna, Jake K. Klaisner
We examine key provisions of Senator Schumer and the Senate Finance Committee’s new Prescription Drug Pricing Reform language, and compare with the Build Back Better Act’s previous version.
Article
A summary of insulin coverage in Medicare Part D
07 June 2022 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Insulin products are widely covered on Part D formularies. In this analysis, all beneficiaries enrolled in an individual Medicare Part D plan have coverage in the classes noted, with a range of coverage options by manufacture and drug type.
Video
Webinar: CY 2023 Medicare bidding hot topics
14 April 2022 - by Haitham Aly, Samantha D’Anna, Jordan Hull, Darin Muse
In this session, Milliman consultants highlight some of the hot topics for Medicare Part C and D bid development for CY2023.